Klotho Neurosciences Files 8-K

Ticker: GRMLW · Form: 8-K · Filed: Jun 16, 2025 · CIK: 1907223

Sentiment: neutral

Topics: corporate-update, filing

Related Tickers: KLTO

TL;DR

Klotho Neurosciences (KLTO) filed an 8-K on 6/16/25. Nothing major, just standard corporate updates.

AI Summary

Klotho Neurosciences, Inc. filed an 8-K on June 16, 2025, reporting on other events and financial statements. The company, formerly known as ANEW Medical, Inc. and Redwoods Acquisition Corp., is incorporated in Delaware and operates in the biological products sector. Its principal executive offices are located at 1115 Broadway, New York, NY.

Why It Matters

This filing provides an update on Klotho Neurosciences' corporate activities and financial reporting, which is crucial for investors to stay informed about the company's status and regulatory compliance.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for corporate updates and does not appear to contain significant new risks or material adverse information.

Key Players & Entities

FAQ

What is the primary business of Klotho Neurosciences, Inc.?

Klotho Neurosciences, Inc. operates in the sector of Biological Products (No Diagnostic Substances), as indicated by its Standard Industrial Classification code [2836].

When was the company formerly known as ANEW Medical, Inc.?

The company's former name was ANEW Medical, Inc. until June 24, 2024.

What is the SEC file number for Klotho Neurosciences, Inc.?

The SEC file number for Klotho Neurosciences, Inc. is 001-41340.

Where are Klotho Neurosciences, Inc.'s principal executive offices located?

Klotho Neurosciences, Inc.'s principal executive offices are located at 1115 Broadway, 12th Floor, New York, NY 10010.

What is the fiscal year end for Klotho Neurosciences, Inc.?

The fiscal year end for Klotho Neurosciences, Inc. is December 31.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 16, 2025 regarding Klotho Neurosciences, Inc. (GRMLW).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing